Literature DB >> 27859054

Alport syndrome: impact of digenic inheritance in patients management.

C Fallerini1, M Baldassarri1,2, E Trevisson3,4, V Morbidoni3,4, A La Manna5, R Lazzarin6, A Pasini7, G Barbano8, A R Pinciaroli9, G Garosi10, E Frullanti1, A M Pinto1,2, M A Mencarelli2, F Mari1,2, A Renieri1,2, F Ariani1,2.   

Abstract

Alport syndrome (ATS) is a genetically heterogeneous nephropathy with considerable phenotypic variability and different transmission patterns, including monogenic (X-linked/autosomal) and digenic inheritance (DI). Here we present a new series of families with DI and we discuss the consequences for genetic counseling and risk assessment. Out of five families harboring variants in more than one COL4 gene detected by next generation sequencing (NGS), minigene-splicing assay allowed us to identify four as true digenic. Two families showed COL4A3/A4 mutations in cis, mimicking an autosomal dominant inheritance with a more severe phenotype and one showed COL4A3/A4 mutations in trans, mimicking an autosomal recessive inheritance with a less severe phenotype. In a fourth family, a de novo mutation (COL4A5) combined with an inherited mutation (COL4A3) triggered a more severe phenotype. A fifth family, predicted digenic on the basis of silico tools, rather showed monogenic X-linked inheritance due to a hypomorphic mutation, in accordance with a milder phenotype. In conclusion, this study highlights the impact of DI in ATS and explains the associated atypical presentations. More complex inheritance should be therefore considered when reviewing prognosis and recurrence risks. On the other side, these findings emphasize the importance to accompany NGS with splicing assays in order to avoid erroneous identification of at risk members.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Alport syndrome; digenic inheritance; hypomorphic allele; massive parallel sequencing

Mesh:

Substances:

Year:  2017        PMID: 27859054     DOI: 10.1111/cge.12919

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  24 in total

Review 1.  Variations of type IV collagen-encoding genes in patients with histological diagnosis of focal segmental glomerulosclerosis.

Authors:  Erol Demir; Yasar Caliskan
Journal:  Pediatr Nephrol       Date:  2019-06-28       Impact factor: 3.714

2.  Alport syndrome: deducing the mode of inheritance from the presence of haematuria in family members.

Authors:  Judy Savige
Journal:  Pediatr Nephrol       Date:  2018-11-30       Impact factor: 3.714

Review 3.  Alport syndrome and Pierson syndrome: Diseases of the glomerular basement membrane.

Authors:  Steven D Funk; Meei-Hua Lin; Jeffrey H Miner
Journal:  Matrix Biol       Date:  2018-04-16       Impact factor: 11.583

4.  Parent-of-origin effect of hypomorphic pathogenic variants and somatic mosaicism impact on phenotypic expression of retinoblastoma.

Authors:  Valentina Imperatore; Anna Maria Pinto; Elisa Gelli; Eva Trevisson; Valeria Morbidoni; Elisa Frullanti; Theodora Hadjistilianou; Sonia De Francesco; Paolo Toti; Elena Gusson; Gaia Roversi; Andrea Accogli; Valeria Capra; Maria Antonietta Mencarelli; Alessandra Renieri; Francesca Ariani
Journal:  Eur J Hum Genet       Date:  2018-04-17       Impact factor: 4.246

5.  Preimplantation Genetic Testing Prevented Intergenerational Transmission of X-Linked Alport Syndrome.

Authors:  Xiaoling Hu; Jiahui Zhang; Yuan Lv; Xijing Chen; Guofang Feng; Liya Wang; Yinghui Ye; Fan Jin; Yimin Zhu
Journal:  Kidney Dis (Basel)       Date:  2021-09-09

6.  Guidelines for Genetic Testing and Management of Alport Syndrome.

Authors:  Judy Savige; Beata S Lipska-Zietkiewicz; Elizabeth Watson; Jens Michael Hertz; Constantinos Deltas; Francesca Mari; Pascale Hilbert; Pavlina Plevova; Peter Byers; Agne Cerkauskaite; Martin Gregory; Rimante Cerkauskiene; Danica Galesic Ljubanovic; Francesca Becherucci; Carmela Errichiello; Laura Massella; Valeria Aiello; Rachel Lennon; Louise Hopkinson; Ania Koziell; Adrian Lungu; Hansjorg Martin Rothe; Julia Hoefele; Miriam Zacchia; Tamara Nikuseva Martic; Asheeta Gupta; Albertien van Eerde; Susie Gear; Samuela Landini; Viviana Palazzo; Laith Al-Rabadi; Kathleen Claes; Anniek Corveleyn; Evelien Van Hoof; Micheel van Geel; Maggie Williams; Emma Ashton; Hendica Belge; Elisabet Ars; Agnieszka Bierzynska; Concetta Gangemi; Alessandra Renieri; Helen Storey; Frances Flinter
Journal:  Clin J Am Soc Nephrol       Date:  2021-12-20       Impact factor: 8.237

7.  Prevalence Estimates of Predicted Pathogenic COL4A3-COL4A5 Variants in a Population Sequencing Database and Their Implications for Alport Syndrome.

Authors:  Joel Gibson; Rachel Fieldhouse; Melanie M Y Chan; Omid Sadeghi-Alavijeh; Leslie Burnett; Valerio Izzi; Anton V Persikov; Daniel P Gale; Helen Storey; Judy Savige
Journal:  J Am Soc Nephrol       Date:  2021-06-18       Impact factor: 14.978

8.  Carrying both COL1A2 and FBN2 gene heterozygous mutations results in a severe skeletal clinical phenotype: an affected family.

Authors:  Jing Chen; Qinqin Xiang; Mei Yang; Shanling Liu; Xiao Xiao; Bocheng Xu; Hanbing Xie; He Wang
Journal:  BMC Med Genomics       Date:  2022-07-08       Impact factor: 3.622

9.  Novel deletion mutation in a Chinese family with X-linked alport syndrome.

Authors:  Yongzhen Li; Qingnan He; Yanran Wang; Ying Wang; Xiqiang Dang; Xiaochuan Wu; Xiaoyan Li; Lanjun Shuai; Zhuwen Yi
Journal:  Int J Clin Exp Pathol       Date:  2018-09-01

10.  Genotype and Outcome After Kidney Transplantation in Alport Syndrome.

Authors:  Valentine Gillion; Karin Dahan; Jean-Pierre Cosyns; Pascale Hilbert; Michel Jadoul; Eric Goffin; Nathalie Godefroid; Martine De Meyer; Michel Mourad; Yves Pirson; Nada Kanaan
Journal:  Kidney Int Rep       Date:  2018-02-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.